FREUD TELEMAQUE

Allopathic & Osteopathic Physicians|Internal Medicine OAKLAND PARK, FL NPI 1902395973

General Payments — all program years on this page

$1,460.77

  • Category: General Payments
  • Program years: PY2019–2024
  • Record count: 74
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $381.93 across 21 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $381.9321

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
PFIZER INC. $170.209
Novo Nordisk AS $74.194
Amgen Inc. $72.674
Lilly USA, LLC $44.743
Boehringer Ingelheim Pharmaceuticals, Inc. $20.131

By program year

Program yearAmountRecords
2019 $83.791
2021 $98.545
2022 $302.1315
2023 $594.3832
2024 $381.9321

Records — PY2024 (21)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1097227811 Novo Nordisk Inc $16.21 10/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097314044 Novo Nordisk Inc $23.30 04/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097354286 Novo Nordisk Inc $20.23 02/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097488196 Novo Nordisk Inc $14.45 03/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111723154 Amgen Inc. $18.20 02/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117397052 Amgen Inc. $18.93 03/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117397054 Amgen Inc. $20.83 04/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117397056 Amgen Inc. $14.71 07/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118226966 Boehringer Ingelheim Pharmaceuticals, Inc. $20.13 10/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1130877418 PFIZER INC. $22.72 10/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1130903244 PFIZER INC. $7.79 03/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131087475 PFIZER INC. $22.76 11/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131177636 PFIZER INC. $18.73 01/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131198515 PFIZER INC. $21.48 02/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131432404 PFIZER INC. $22.69 12/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131708429 PFIZER INC. $21.80 06/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131793283 PFIZER INC. $15.92 07/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131998273 PFIZER INC. $16.31 09/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1134981554 Lilly USA, LLC $15.88 06/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1134983752 Lilly USA, LLC $14.87 05/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1134992244 Lilly USA, LLC $13.99 07/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.